TMO ($478.88) is trading below its intrinsic value of $1,020.07, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Valuation
TMO is poor value based on its earnings relative to its share price (29.76x), compared to the US market average (18.56x)
Valuation
TMO is good value based on its earnings relative to its share price (29.76x), compared to the US Diagnostics & Research industry average (46.83x)
Valuation
1 of 13
TMO News
Valuation
TMO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
29.76x
Industry
46.83x
Market
18.56x
TMO is poor value based on its earnings relative to its share price (29.76x), compared to the US market average (18.56x)
Valuation
TMO is good value based on its earnings relative to its share price (29.76x), compared to the US Diagnostics & Research industry average (46.83x)
Valuation
TMO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.5x
Industry
5.92x
Market
-0.01x
TMO is good value based on its book value relative to its share price (5.5x), compared to the US market average (-0.01x)
Valuation
TMO is good value based on its book value relative to its share price (5.5x), compared to the US Diagnostics & Research industry average (5.92x)
Valuation
TMO price to earnings growth (PEG)
For valuing profitable companies with growth potential
TMO is poor value relative to its rate of earnings growth, measured by PEG ratio (2.08x)
Valuation
TMO's financial health
Profit margin
Revenue
$10.6B
Net Income
$2.5B
Profit Margin
23.7%
TMO's Earnings (EBIT) of $7.78B can safely cover interest payments on company debt ($21.74B)
Financials
TMO's profit margin has increased (+5.3%) in the last year from (14.5%) to (19.8%)
Financials
Assets to liabilities
Assets
$69.1B
Liabilities
$34.5B
Debt to equity
0.63
TMO's short-term assets ($21.96B) exceed its short-term liabilities ($10.30B)
Financials
TMO's long-term liabilities ($24.24B) exceed its short-term assets ($21.96B)
Financials
TMO's debt has increased relative to shareholder equity (1), over the past 5 years ago (0.91)
Financials
TMO's debt to equity ratio (1) is considered high
Financials
Cash flow
Operating
$3.3B
Investing
-$626.0M
Financing
-$49.0M
TMO's operating cash flow ($8.29B) is sufficient to service the company's debt ($21.74B)
Financials
Thermo Fisher Scientific Stock FAQ
What is Thermo Fisher Scientific's quote symbol?
(NYSE: TMO) Thermo Fisher Scientific trades on the NYSE under the ticker symbol TMO. Thermo Fisher Scientific stock quotes can also be displayed as NYSE: TMO.
What is the 52 week high and low for Thermo Fisher Scientific (NYSE: TMO)?
(NYSE: TMO) Thermo Fisher Scientific's 52-week high was $532.57, and its 52-week low was $309.18. It is currently -10.08% from its 52-week high and 54.89% from its 52-week low.
How much is Thermo Fisher Scientific stock worth today?
(NYSE: TMO) Thermo Fisher Scientific currently has 396,335,191 outstanding shares. With Thermo Fisher Scientific stock trading at $478.88 per share, the total value of Thermo Fisher Scientific stock (market capitalization) is $189.80B.
Thermo Fisher Scientific stock was originally listed at a price of $44.00 in Dec 31, 1997. If you had invested in Thermo Fisher Scientific stock at $44.00, your return over the last 23 years would have been 988.36%, for an annualized return of 10.94%.
How much is Thermo Fisher Scientific's stock price per share?
(NYSE: TMO) Thermo Fisher Scientific stock price per share is $478.88 today (as of Apr 9, 2021).
What is Thermo Fisher Scientific's Market Cap?
(NYSE: TMO) Thermo Fisher Scientific's market cap is $189.80B, as of Apr 11, 2021.
Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.
Thermo Fisher Scientific's market cap is calculated by multiplying TMO's current stock price of $478.88 by TMO's total outstanding shares of 396,335,191.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.